systemic lupus erythematosus
Information
- Disease name
- systemic lupus erythematosus
- Disease ID
- DOID:9074
- Description
- "A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart." [url:http\://en.wikipedia.org/wiki/Systemic_lupus_erythematosus] {comment="ls:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT06029335 | Active, not recruiting | Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases | September 1, 2020 | August 30, 2023 | |
NCT05155345 | Active, not recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus | January 11, 2022 | June 1, 2025 |
NCT03938324 | Active, not recruiting | N/A | Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions | October 29, 2019 | May 2024 |
NCT05162586 | Active, not recruiting | Phase 2 | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) | March 31, 2022 | August 16, 2024 |
NCT04294667 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | August 12, 2020 | September 30, 2024 |
NCT03735238 | Active, not recruiting | Implementing the Decision-Aid for Lupus (IDEAL Strategy) | December 15, 2018 | December 15, 2025 | |
NCT05328557 | Active, not recruiting | Phase 1 | A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers | November 7, 2021 | December 31, 2023 |
NCT05116163 | Active, not recruiting | N/A | Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology | June 17, 2022 | August 15, 2024 |
NCT05347992 | Active, not recruiting | ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation) | May 3, 2022 | March 1, 2025 | |
NCT04335643 | Active, not recruiting | N/A | Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus | August 4, 2020 | August 24, 2024 |
NCT01729455 | Active, not recruiting | Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry | February 21, 2013 | February 17, 2025 | |
NCT03030118 | Active, not recruiting | Phase 2 | Study of Anti-Malarials in Incomplete Lupus Erythematosus | December 28, 2017 | January 2025 |
NCT01649765 | Active, not recruiting | Phase 2 | Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy | September 7, 2012 | April 5, 2028 |
NCT05478018 | Active, not recruiting | N/A | Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients | April 1, 2022 | September 1, 2024 |
NCT04179032 | Active, not recruiting | Phase 2 | Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) | November 28, 2019 | April 23, 2027 |
NCT03684564 | Active, not recruiting | Phase 2 | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | July 9, 2021 | August 2025 |
NCT03920267 | Active, not recruiting | Phase 2 | Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus | March 26, 2019 | March 31, 2025 |
NCT05087628 | Active, not recruiting | Phase 2 | PRV-3279-2a Trial in Systemic Lupus | January 24, 2022 | September 2025 |
NCT03734055 | Active, not recruiting | N/A | Peer Approaches to Lupus Self-management | November 30, 2018 | September 25, 2024 |
NCT04882878 | Active, not recruiting | Phase 2 | A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus | August 20, 2021 | December 26, 2024 |
NCT03915652 | Active, not recruiting | N/A | Addressing Disparities in Lupus Care Through an Integrated Care Management Program | June 21, 2019 | December 30, 2023 |
NCT04835441 | Active, not recruiting | Phase 2 | ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus | June 22, 2021 | January 2025 |
NCT04184258 | Completed | Phase 1/Phase 2 | Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells | July 1, 2019 | December 31, 2020 |
NCT04186871 | Completed | Phase 2 | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | January 7, 2020 | December 5, 2022 |
NCT04239521 | Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata | October 1, 2020 | November 28, 2022 | |
NCT00000416 | Completed | N/A | Prevention of Arthritis-Related Work Disability | September 1997 | August 2001 |
NCT00418587 | Completed | Phase 1 | Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE) | December 2006 | August 2014 |
NCT04305197 | Completed | Phase 1/Phase 2 | A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) | July 9, 2020 | April 28, 2022 |
NCT04345159 | Completed | Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease | April 17, 2020 | November 30, 2020 | |
NCT04355702 | Completed | Covid-19 in Lupus Patients | March 1, 2020 | December 30, 2020 | |
NCT00342095 | Completed | Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study | December 17, 1996 | March 7, 2007 | |
NCT04358302 | Completed | N/A | Individual Patient Exposure and Response in Pediatric Lupus | September 28, 2020 | June 16, 2021 |
NCT04397107 | Completed | N/A | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases | August 15, 2020 | June 30, 2022 |
NCT00371501 | Completed | Phase 4 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus | June 2006 | December 2009 |
NCT04400240 | Completed | N/A | Care Coordination Approaches to Learning Lupus Self-management | January 1, 2018 | December 31, 2019 |
NCT04411407 | Completed | N/A | PROM Collected Via a WebApp Versus a Touch Screen Solution Among Patients With SLE | July 15, 2020 | November 25, 2020 |
NCT04433585 | Completed | Phase 2 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | August 19, 2020 | February 16, 2023 |
NCT04440566 | Completed | N/A | O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus | October 13, 2020 | February 14, 2022 |
NCT04453215 | Completed | N/A | Laser Therapy for Patients With Systemic Lupus Erythematosus | January 12, 2019 | March 15, 2020 |
NCT00417430 | Completed | Phase 2 | Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies | September 2004 | December 2006 |
NCT00383513 | Completed | Phase 2 | Study of Epratuzumab in Systemic Lupus Erythematosus | June 2006 | January 2012 |
NCT04570306 | Completed | Transcriptional and Immune Parameters of Response to Belimumab | December 16, 2020 | December 16, 2023 | |
NCT04580108 | Completed | Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus | July 3, 2007 | June 26, 2019 | |
NCT00004665 | Completed | Phase 2 | Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus | June 1995 | |
NCT04647708 | Completed | Phase 1 | Study of M5049 in CLE and SLE Participants | December 16, 2020 | December 19, 2023 |
NCT00392093 | Completed | Phase 4 | Effect of Hormone Replacement Therapy on Lupus Activity | November 1997 | December 2001 |
NCT00413361 | Completed | Phase 4 | The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS | June 2007 | January 2011 |
NCT00493753 | Completed | N/A | Feasibility and Safety of Acupuncture for Systemic Lupus | November 2004 | April 2006 |
NCT03802578 | Completed | N/A | The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients | September 28, 2016 | September 30, 2018 |
NCT00235378 | Completed | Genetic Study of Lupus Patients and Their Families | July 1996 | March 2013 | |
NCT06073613 | Completed | Periodontal Status in Patients With Chronic Skin Diseases | January 20, 2023 | April 28, 2023 | |
NCT03817424 | Completed | Phase 1 | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | December 13, 2018 | July 20, 2020 |
NCT00000417 | Completed | Phase 2 | Psychoeducational Approach to Improve Health in Lupus | April 1997 | March 2001 |
NCT03845517 | Completed | Phase 2 | A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | April 18, 2019 | October 5, 2023 |
NCT00271934 | Completed | Phase 2 | Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study | September 2002 | April 2012 |
NCT00278538 | Completed | Phase 2 | Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus | September 23, 2005 | May 2019 |
NCT05048238 | Completed | Phase 1 | Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus | September 30, 2022 | February 29, 2024 |
NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
NCT03942718 | Completed | N/A | Systemic Lupus Erythematosus Exercise Program | March 21, 2018 | August 1, 2020 |
NCT03949426 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects | May 1, 2019 | September 29, 2019 |
NCT03951259 | Completed | Phase 2 | Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | July 24, 2019 | October 19, 2023 |
NCT00424476 | Completed | Phase 3 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | May 2007 | March 2010 |
NCT03979976 | Completed | Phase 2/Phase 3 | Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus | March 2011 | September 2013 |
NCT00280137 | Completed | Health-related Quality of Life Measure in Pediatric Lupus | June 2004 | December 2013 | |
NCT04082416 | Completed | Phase 3 | Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) | October 16, 2019 | June 30, 2022 |
NCT00293072 | Completed | Phase 2 | Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis | March 2002 | May 2005 |
NCT04136145 | Completed | Phase 1 | Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects | October 28, 2019 | January 14, 2020 |
NCT05001698 | Completed | Phase 1 | Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE) | July 27, 2021 | June 2, 2022 |
NCT04180228 | Completed | Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Diseases. | January 23, 2020 | May 4, 2021 | |
NCT02908100 | Completed | Phase 2 | A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus | January 19, 2017 | July 16, 2019 |
NCT05146414 | Completed | Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus | July 10, 2007 | February 10, 2021 | |
NCT02925351 | Completed | Early Phase 1 | Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases | January 25, 2016 | April 30, 2018 |
NCT02932137 | Completed | N/A | Anti-infection of Low-does IL-2 in SLE | May 5, 2016 | August 30, 2017 |
NCT02950714 | Completed | N/A | Dissemination of the Lupus Interactive Navigator | October 30, 2017 | July 31, 2018 |
NCT02955615 | Completed | Phase 2 | ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) | January 18, 2017 | February 11, 2019 |
NCT02962960 | Completed | Phase 2 | A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations | February 14, 2017 | December 17, 2018 |
NCT05123586 | Completed | Phase 2 | A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus | March 7, 2022 | December 29, 2023 |
NCT03093402 | Completed | Phase 2 | JBT-101 in Systemic Lupus Erythematosus (SLE) | December 21, 2017 | July 28, 2021 |
NCT03107442 | Completed | N/A | Exercise and Arterial Stiffness in Systemic Lupus Erythematosus | April 12, 2017 | July 21, 2017 |
NCT00119678 | Completed | Phase 2 | Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone | September 2005 | November 2008 |
NCT03142711 | Completed | Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus | August 21, 2017 | July 3, 2018 | |
NCT00120887 | Completed | Phase 4 | Lupus Atherosclerosis Prevention Study | April 2002 | December 2005 |
NCT00124514 | Completed | Phase 2 | Triptorelin for Ovary Protection in Childhood Onset Lupus | June 2003 | March 2014 |
NCT00155532 | Completed | Phase 1 | Skin Denervation in Systemic Lupus Erythematosus | April 2002 | March 2004 |
NCT03179046 | Completed | Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus | April 1, 2018 | July 1, 2019 | |
NCT05115370 | Completed | Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19 | November 1, 2021 | January 14, 2022 | |
NCT03189017 | Completed | Phase 1 | A Phase I Study of ICP-022 in Healthy Subjects | July 3, 2017 | October 30, 2018 |
NCT03189875 | Completed | Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) | June 28, 2017 | November 18, 2022 | |
NCT03206359 | Completed | GADD34 and Type I IFN Response Genes in SLE | January 25, 2012 | April 3, 2015 | |
NCT00001212 | Completed | Phase 2 | Drug Therapy in Lupus Nephropathy | November 1986 | September 2004 |
NCT03252587 | Completed | Phase 2 | An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus | September 21, 2017 | October 28, 2021 |
NCT03254784 | Completed | Phase 1 | A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation | September 13, 2017 | November 15, 2017 |
NCT03262727 | Completed | Phase 1 | The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients | September 1, 2017 | December 19, 2017 |
NCT03288324 | Completed | Phase 1/Phase 2 | Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus | August 23, 2017 | December 1, 2022 |
NCT00181298 | Completed | N/A | Memantine in Systemic Lupus Erythematosus | March 2006 | May 2007 |
NCT03312907 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE | March 1, 2018 | July 7, 2021 |
NCT03334851 | Completed | Phase 1 | Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis | November 17, 2017 | February 15, 2022 |
NCT03371251 | Completed | Phase 1/Phase 2 | Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care | January 10, 2018 | November 26, 2020 |
NCT03374618 | Completed | N/A | Neutrophil Extracellular Traps in Systemic Sclerosis | February 23, 2018 | April 29, 2021 |
NCT03393013 | Completed | Phase 1/Phase 2 | A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis | February 20, 2018 | August 4, 2022 |
NCT00001676 | Completed | Phase 1 | Cyclophosphamide and Fludarabine to Treat Lupus Nephritis | January 1998 | November 2002 |
NCT00189124 | Completed | Phase 2/Phase 3 | Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention | September 2003 | July 2006 |
NCT03451422 | Completed | Phase 1 | Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus | April 10, 2018 | October 12, 2021 |
NCT06046534 | Completed | Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs. | October 27, 2023 | June 10, 2024 | |
NCT03480529 | Completed | Monitoring the IMmUological TOXicity of Drugs | March 1, 2018 | March 10, 2018 | |
NCT03537638 | Completed | N/A | Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE | April 16, 2018 | December 31, 2020 |
NCT03541564 | Completed | Phase 1 | An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects | May 30, 2018 | September 4, 2018 |
NCT03556007 | Completed | Phase 1 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | April 18, 2018 | August 29, 2019 |
NCT03575156 | Completed | N/A | Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis | September 20, 2018 | September 14, 2021 |
NCT00470522 | Completed | Phase 3 | Study of Methotrexate in Lupus Erythematosus | June 1995 | December 2001 |
NCT00004662 | Completed | Phase 3 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus | March 1996 | |
NCT03616964 | Completed | Phase 3 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) | August 2, 2018 | October 20, 2021 |
NCT03618056 | Completed | Phase 1 | Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus | December 19, 2018 | July 17, 2020 |
NCT03724916 | Completed | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) | November 26, 2018 | November 4, 2021 |
NCT03738826 | Completed | N/A | Reducing Disparities in Medication Adherence in SLE | October 2, 2019 | June 7, 2020 |
NCT03742037 | Completed | Phase 2 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | December 21, 2018 | August 25, 2022 |
NCT00541749 | Completed | Phase 1 | A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus | February 2007 | |
NCT04786431 | Completed | Shotgun Mass Spectrometry-based Lipid Profiling in Chronic Inflammatory Diseases | March 1, 2015 | March 1, 2021 | |
NCT00401141 | Completed | N/A | Abnormalities of B Lymphocytes During Systemic Lupus | April 2004 | |
NCT00410384 | Completed | Phase 3 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | December 2006 | March 2010 |
NCT00544102 | Completed | Insulin Resistance and Atherosclerosis in Women With Lupus | October 11, 2007 | September 7, 2017 | |
NCT00556192 | Completed | Phase 2 | Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus | June 2006 | December 2009 |
NCT04857151 | Completed | Early Phase 1 | Stress, Inflammation and Immune Response Pilot Study- Aim 3 | February 2, 2022 | March 31, 2024 |
NCT04873739 | Completed | AS-OCT Study of Cornea and Tear Film Parameters in SLE Patients | July 1, 2020 | March 30, 2021 | |
NCT00583362 | Completed | Phase 2 | A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 | May 4, 2005 | February 23, 2016 |
NCT00588393 | Completed | Phase 2 | FolateScan in Autoimmune Disease | September 2006 | December 2007 |
NCT00594932 | Completed | Phase 1/Phase 2 | Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis | November 2006 | April 2009 |
NCT00611611 | Completed | BLYS and IFN in SLE | October 2007 | April 2009 | |
NCT00624351 | Completed | Phase 2 | Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease | January 2008 | August 2009 |
NCT00657007 | Completed | Phase 1 | Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | February 2002 | March 2003 |
NCT00660881 | Completed | Phase 2 | Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease | May 2008 | December 2011 |
NCT00668330 | Completed | Phase 4 | Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus | April 2007 | May 2009 |
NCT00004756 | Completed | N/A | Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus | December 1994 | |
NCT00710021 | Completed | Phase 2 | Vitamin D3 in Systemic Lupus Erythematosus | November 2008 | July 2011 |
NCT00712933 | Completed | Phase 3 | A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 | May 30, 2008 | December 9, 2016 |
NCT00723671 | Completed | N/A | Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus | November 2006 | December 2013 |
NCT00724867 | Completed | Phase 3 | A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States | August 2008 | March 2015 |
NCT00731302 | Completed | Phase 1 | Aspirin Resistance in Systemic Lupus Erythematosus (SLE) | April 2005 | April 2017 |
NCT00004795 | Completed | Phase 2/Phase 3 | Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus | August 1994 | |
NCT00774943 | Completed | Phase 1 | A Study of AMG 557 in Adults With Systemic Lupus Erythematosus | December 2008 | May 2012 |
NCT00786409 | Completed | N/A | Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women | November 2008 | December 2011 |
NCT00815282 | Completed | Phase 4 | Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease | February 2009 | January 2015 |
NCT00818948 | Completed | Phase 1 | Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis | March 2009 | August 2014 |
NCT00828178 | Completed | Phase 4 | Efficacy of Fish Oil in Lupus Patients | February 2009 | February 2011 |
NCT05430087 | Completed | Phase 2 | Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients | March 1, 2020 | January 31, 2022 |
NCT00006133 | Completed | N/A | Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus | June 2000 | |
NCT00911521 | Completed | Phase 4 | Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study | October 2009 | June 2011 |
NCT00962832 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus | September 2009 | August 2013 |
NCT00976300 | Completed | Phase 2 | Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study | January 2002 | April 2009 |
NCT00976729 | Completed | Phase 1 | NOX-E36 First-in-Human (FIH) Study | May 2009 | December 2009 |
NCT00979654 | Completed | Phase 2 | A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis | August 2010 | March 2015 |
NCT00982670 | Completed | A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus | July 2008 | June 2009 | |
NCT00006134 | Completed | Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture | September 1993 | ||
NCT00987831 | Completed | Phase 1/Phase 2 | Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) | May 2009 | December 2012 |
NCT00997100 | Completed | Phase 2 | Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) | August 2009 | September 2010 |
NCT01031836 | Completed | Phase 2 | A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. | November 25, 2009 | July 11, 2016 |
NCT01058343 | Completed | Phase 1/Phase 2 | Safety of IFNa Kinoid in Systemic Lupus Erythematosus | March 2010 | June 2016 |
NCT01076101 | Completed | Autoimmunity in Sisters of Lupus Patients | February 2009 | December 31, 2016 | |
NCT01101802 | Completed | Phase 4 | Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) | March 2006 | October 2008 |
NCT01112215 | Completed | Phase 4 | Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations | December 2009 | December 2015 |
NCT01120652 | Completed | N/A | Reducing Depressive Symptoms in Systemic Lupus Erythematosus | November 2009 | September 2015 |
NCT01135459 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) | June 24, 2010 | June 30, 2012 |
NCT01157468 | Completed | Catalytic Antibodies and Lupus in Martinique | January 2012 | December 2013 | |
NCT01162681 | Completed | Phase 2 | PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus | July 2010 | April 2012 |
NCT05426902 | Completed | N/A | Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE) | January 3, 2022 | June 30, 2022 |
NCT01170585 | Completed | Phase 2 | A Trial of Rosuvastatin in Systemic Lupus Erythematosus | July 2010 | June 2014 |
NCT01176643 | Completed | N/A | Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE) | August 2010 | August 2013 |
NCT01196091 | Completed | Phase 3 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | December 2010 | June 2015 |
NCT01205438 | Completed | Phase 3 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | January 2011 | March 2015 |
NCT01230112 | Completed | The Role of ITGAM in Systemic Lupus Erythematosus | December 2009 | April 2012 | |
NCT01261793 | Completed | Phase 3 | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) | December 2010 | June 2015 |
NCT01262365 | Completed | Phase 3 | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus | December 2010 | May 2015 |
NCT01269866 | Completed | N/A | Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus | December 2010 | May 2012 |
NCT01283139 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus | March 31, 2011 | April 17, 2014 |
NCT01305746 | Completed | Phase 2 | A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 | April 2011 | October 2013 |
NCT01322308 | Completed | Phase 4 | Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus | March 2007 | January 2012 |
NCT01330368 | Completed | Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children | October 2010 | June 2017 | |
NCT01345253 | Completed | Phase 3 | GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia | May 23, 2011 | September 21, 2018 |
NCT01351662 | Completed | Phase 1/Phase 2 | Balancing Lupus Experiences With Stress Strategies | August 2010 | October 2011 |
NCT01381536 | Completed | Phase 1 | Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE) | July 20, 2010 | November 27, 2010 |
NCT01395745 | Completed | Phase 3 | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus | February 2013 | October 2016 |
NCT01408576 | Completed | Phase 3 | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus | July 2011 | February 2016 |
NCT01425775 | Completed | N/A | The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE) | April 2010 | May 2011 |
NCT01438489 | Completed | Phase 2 | A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus | January 2012 | April 2015 |
NCT01449071 | Completed | Phase 1/Phase 2 | Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) | October 2011 | March 2013 |
NCT00010335 | Completed | Phase 1 | Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders | November 2000 | May 2011 |
NCT01474720 | Completed | Phase 1 | Zostavax in Systemic Lupus Erythematosus | November 2011 | October 2012 |
NCT01475149 | Completed | Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) | September 2010 | August 2016 | |
NCT01484496 | Completed | Phase 3 | A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) | November 16, 2011 | October 1, 2015 |
NCT00522002 | Completed | CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study | August 2007 | June 2010 | |
NCT01509989 | Completed | International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus | January 2013 | March 2016 | |
NCT00010400 | Completed | N/A | Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome | April 1997 | |
NCT01516450 | Completed | Phase 1 | Japanese phase1 Study of Belimumab (IV vs SC) | December 26, 2011 | April 11, 2012 |
NCT01520155 | Completed | CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE) | December 2011 | December 2012 | |
NCT01532310 | Completed | Belimumab (BENLYSTA®) Pregnancy Registry | July 16, 2012 | November 11, 2022 | |
NCT01534403 | Completed | Phase 2 | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects | January 2012 | February 2015 |
NCT00004663 | Completed | Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus | February 1994 | ||
NCT01549184 | Completed | Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia | December 2010 | December 2011 | |
NCT01559090 | Completed | Phase 2 | Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus. | April 20, 2012 | February 21, 2017 |
NCT01597492 | Completed | Phase 4 | A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) | May 31, 2012 | September 24, 2015 |
NCT01597622 | Completed | Phase 3 | BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 | June 11, 2012 | September 13, 2018 |
NCT01616472 | Completed | WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins) | April 2012 | January 2016 | |
NCT01632241 | Completed | Phase 4 | Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) | February 19, 2013 | January 28, 2019 |
NCT00011908 | Completed | Phase 1 | Humanized LL2IGG to Treat Systemic Lupus Erythematosus | February 2001 | January 2003 |
NCT00000420 | Completed | Phase 3 | Safety of Estrogens in Lupus: Birth Control Pills | June 1997 | August 2003 |
NCT01687309 | Completed | Phase 1 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender | April 30, 2012 | July 31, 2012 |
NCT00519363 | Completed | Phase 1/Phase 2 | Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors | September 2007 | December 2008 |
NCT01689350 | Completed | N/A | A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment | October 2012 | March 2014 |
NCT01697254 | Completed | The CARRA Registry | August 2009 | October 2015 | |
NCT01705977 | Completed | Phase 4 | Belimumab Assessment of Safety in SLE | November 27, 2012 | August 10, 2022 |
NCT00513591 | Completed | Duke Autoimmunity in Pregnancy Registry | August 2007 | November 19, 2018 | |
NCT00035308 | Completed | Phase 3 | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease | December 2002 | |
NCT01741012 | Completed | Phase 1 | Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients | January 2013 | November 2015 |
NCT00000421 | Completed | Phase 2 | Serologically Active, Clinically Stable Systemic Lupus Erythematosus | September 1997 | August 2003 |
NCT05329831 | Completed | N/A | Effects of Telehealth Initiative on Lupus Patients | March 15, 2022 | June 30, 2022 |
NCT01837875 | Completed | N/A | Intervention to Improve Quality of Life in African American Lupus Patients | April 2013 | August 31, 2016 |
NCT00042523 | Completed | Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus | July 2002 | January 2005 | |
NCT00046774 | Completed | Phase 1 | Monoclonal Antibody Treatment for Systemic Lupus Erythematosus | September 2, 2002 | September 7, 2017 |
NCT01892748 | Completed | N/A | Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. | July 2012 | February 2014 |
NCT01894360 | Completed | Phase 1 | A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects | October 14, 2013 | May 13, 2014 |
NCT01911169 | Completed | Phase 2 | Vitamin D to Improve Endothelial Function in SLE | June 2011 | January 2014 |
NCT01914770 | Completed | Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76 | July 2009 | November 2010 | |
NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
NCT01953835 | Completed | Phase 1 | A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184 | October 4, 2013 | March 10, 2014 |
NCT00054938 | Completed | Phase 2 | Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) | March 2003 | December 2005 |
NCT01988506 | Completed | Phase 2 | Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases | January 6, 2014 | April 1, 2021 |
NCT02021513 | Completed | Phase 2 | Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus | January 2012 | June 2013 |
NCT00055055 | Completed | Study of Families With Twins or Siblings Discordant for Rheumatic Disorders | April 21, 2003 | ||
NCT05287581 | Completed | N/A | Motivating Individuals With Lupus to Exercise | January 17, 2022 | October 31, 2023 |
NCT02084238 | Completed | N/A | Low-dose IL-2( Interleukin-2) Treatment in SLE | August 2013 | October 2015 |
NCT02106897 | Completed | Phase 1 | Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus | April 30, 2014 | May 24, 2016 |
NCT02119156 | Completed | Phase 3 | Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients | May 13, 2014 | December 14, 2018 |
NCT02124798 | Completed | Phase 2 | A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector | May 20, 2014 | April 13, 2015 |
NCT02151409 | Completed | Phase 1 | Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects | June 2008 | October 2009 |
NCT02185040 | Completed | Phase 2 | A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. | September 16, 2014 | September 25, 2018 |
NCT02194400 | Completed | Phase 1 | Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus | July 2014 | November 2015 |
NCT02270957 | Completed | Phase 2 | Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches | January 2014 | December 2021 |
NCT00069342 | Completed | Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases | September 22, 2003 | April 12, 2018 | |
NCT02281513 | Completed | N/A | Activity and Nutrition Trial in Lupus to Energize and Renew | October 2014 | September 11, 2023 |
NCT02291588 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus | December 2007 | June 2010 |
NCT02306629 | Completed | Phase 1 | Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood | November 2014 | April 2015 |
NCT02307643 | Completed | Phase 1 | Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients | February 2015 | May 2017 |
NCT02319525 | Completed | N/A | Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus | January 2014 | December 2016 |
NCT02321709 | Completed | Phase 1 | Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients | November 2014 | March 2016 |
NCT02330250 | Completed | N/A | Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment | July 2014 | June 2016 |
NCT02338999 | Completed | Phase 1/Phase 2 | Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) | June 18, 2015 | July 14, 2020 |
NCT02350491 | Completed | Study During Pregnancy of Expression of miRNAs in RA or SLE | December 17, 2017 | October 14, 2018 | |
NCT02364908 | Completed | N/A | Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus | December 2014 | December 2016 |
NCT02391259 | Completed | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | November 2006 | November 2011 |
NCT00071175 | Completed | Lupus Genetics Studies | October 1995 | November 2013 | |
NCT05247203 | Completed | Phase 1 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | May 11, 2022 | November 13, 2023 |
NCT02411136 | Completed | Phase 1 | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus | May 2005 | October 2007 |
NCT02443506 | Completed | Phase 1 | A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus | October 2004 | June 2007 |
NCT02453880 | Completed | N/A | Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness | January 2014 | August 2015 |
NCT02456168 | Completed | Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus | January 21, 2014 | October 28, 2020 | |
NCT00074373 | Completed | The Research Registry for Neonatal Lupus | May 27, 2010 | June 2016 | |
NCT02472795 | Completed | Phase 1/Phase 2 | Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus | June 1, 2015 | February 28, 2017 |
NCT02477150 | Completed | Phase 4 | Safety and Immunogenicity of a Zoster Vaccine in SLE | November 2015 | January 2019 |
NCT02477254 | Completed | Long-term Immunogenicity of a HPV Vaccine in SLE | July 2015 | October 2016 | |
NCT05203692 | Completed | Phase 1 | A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects | February 2, 2022 | March 22, 2023 |
NCT02524795 | Completed | N/A | Omega 3 Fatty Acids and Systemic Lupus Erythematosus | March 2009 | March 2014 |
NCT02530944 | Completed | Web-based Genetic Research on Lupus | May 2015 | October 31, 2017 | |
NCT03757065 | Completed | Cell Surface Marker Expression in Autoimmune Diseases | June 12, 2019 | October 25, 2019 | |
NCT02535689 | Completed | Phase 1 | Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus | August 28, 2015 | April 26, 2018 |
NCT02554019 | Completed | Phase 2 | Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus | September 28, 2015 | October 25, 2017 |
NCT02554474 | Completed | N/A | OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis | January 1, 2017 | August 25, 2019 |
NCT00082511 | Completed | Phase 3 | GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | July 2003 | August 2005 |
NCT02609789 | Completed | Phase 1 | A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus | December 2015 | September 2018 |
NCT02618967 | Completed | Phase 1 | Single Ascending Dose Study of AMG 570 in Healthy Subjects | March 28, 2016 | December 3, 2018 |
NCT02631005 | Completed | N/A | Walk With Ease Program For Patients With Systemic Lupus Erythematosus | March 2016 | August 30, 2018 |
NCT02660944 | Completed | Phase 2 | A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) | January 3, 2016 | August 10, 2020 |
NCT02708095 | Completed | Phase 2 | A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) | March 24, 2016 | November 9, 2017 |
NCT02725515 | Completed | Phase 2 | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | February 16, 2016 | July 17, 2018 |
NCT00483613 | Completed | N/A | Effects of Treatment of Chronic Stress in Patients With Lupus | December 2003 | July 2005 |
NCT02741960 | Completed | Phase 4 | The Effect of Metformin on Reducing Lupus Flares | May 24, 2016 | December 7, 2018 |
NCT02769195 | Completed | Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE | April 2016 | January 2019 | |
NCT02842814 | Completed | N/A | Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus | October 2016 | September 28, 2022 |
NCT02847598 | Completed | Phase 2 | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | October 20, 2016 | November 18, 2019 |
NCT02880852 | Completed | Phase 1 | Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus | January 23, 2017 | September 8, 2017 |
NCT02885610 | Completed | Phase 2 | Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) | December 2015 | July 9, 2019 |
NCT04976322 | Enrolling by invitation | Phase 3 | A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus | July 27, 2021 | April 10, 2029 |
NCT06294483 | Enrolling by invitation | Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. | January 10, 2024 | August 30, 2024 | |
NCT04750057 | No longer available | Anifrolumab Early Access Program | |||
NCT03125486 | No longer available | Compassionate Use for Subcutaneous (SC) Belimumab | |||
NCT06106906 | Not yet recruiting | Phase 1/Phase 2 | A Clinical Study of CD19 CAR-T in Refractory/Moderate-to-severe Systemic Lupus Erythematosus | December 2023 | December 2026 |
NCT06417398 | Not yet recruiting | Early Phase 1 | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | May 14, 2024 | May 1, 2025 |
NCT05613582 | Not yet recruiting | N/A | The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus Erythematosus | November 20, 2022 | September 20, 2023 |
NCT06404723 | Not yet recruiting | The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients | June 1, 2024 | April 1, 2025 | |
NCT04902807 | Not yet recruiting | Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation | June 2021 | December 2024 | |
NCT06350110 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) | November 10, 2024 | December 28, 2025 |
NCT06255028 | Not yet recruiting | Phase 1 | A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) | August 2024 | August 2028 |
NCT04671706 | Not yet recruiting | Belimumab in Patients With Systemic Lupus Erythematosus | January 2021 | December 2026 | |
NCT04893161 | Not yet recruiting | Phase 4 | A Model About the Response of Belimumab in SLE | June 1, 2024 | January 31, 2026 |
NCT06411639 | Not yet recruiting | Phase 1 | Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases | November 25, 2024 | June 24, 2028 |
NCT06340750 | Not yet recruiting | Phase 1 | BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus | June 1, 2024 | April 15, 2026 |
NCT06227559 | Not yet recruiting | The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus | February 1, 2024 | June 1, 2024 | |
NCT06413511 | Not yet recruiting | Phase 1 | A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus | May 29, 2024 | November 24, 2025 |
NCT06456567 | Not yet recruiting | Phase 3 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) | July 2024 | April 2027 |
NCT05544448 | Not yet recruiting | N/A | In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases | October 15, 2022 | April 15, 2023 |
NCT06340490 | Not yet recruiting | Phase 1 | A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) | May 15, 2024 | December 31, 2027 |
NCT06365359 | Not yet recruiting | Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique | April 15, 2024 | November 15, 2025 | |
NCT05516511 | Not yet recruiting | Serum Levels of Angiotensin Converting Enzyme in Systemic Lupus Erythematous Patients | January 2023 | March 2023 | |
NCT06394063 | Not yet recruiting | N/A | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients | June 30, 2024 | June 30, 2027 |
NCT05929248 | Not yet recruiting | Phase 2 | Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia | July 1, 2023 | December 30, 2024 |
NCT06465147 | Not yet recruiting | Phase 1 | REACT-01: Reversing Autoimmunity Through Cell Therapy | July 2024 | July 2041 |
NCT06293365 | Not yet recruiting | Phase 2 | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | June 26, 2024 | February 8, 2029 |
NCT05799378 | Not yet recruiting | Phase 3 | Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | April 2024 | December 21, 2028 |
NCT05504187 | Not yet recruiting | Phase 2 | Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus | October 2023 | October 2024 |
NCT06458075 | Not yet recruiting | N/A | Intervention to Improve Communication and Medication Adherence in Lupus | July 2024 | December 2028 |
NCT06349343 | Not yet recruiting | Phase 1 | CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus | April 2024 | January 2026 |
NCT05465707 | Not yet recruiting | Phase 1/Phase 2 | A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus | October 30, 2022 | October 30, 2023 |
NCT06448273 | Not yet recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects | July 2024 | October 2024 |
NCT06228222 | Not yet recruiting | Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals. | January 25, 2024 | October 1, 2025 | |
NCT05818254 | Not yet recruiting | N/A | The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB | May 31, 2024 | March 31, 2026 |
NCT06238531 | Not yet recruiting | Phase 1 | A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus | June 23, 2024 | October 1, 2028 |
NCT05424627 | Not yet recruiting | Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus | July 15, 2022 | January 15, 2027 | |
NCT06379646 | Not yet recruiting | N/A | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease | April 22, 2024 | April 21, 2026 |
NCT06356740 | Not yet recruiting | Phase 2 | Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus | September 1, 2024 | June 1, 2029 |
NCT06188507 | Not yet recruiting | Phase 1 | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants | January 11, 2024 | March 31, 2025 |
NCT06421701 | Not yet recruiting | Phase 1 | Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus | June 1, 2024 | May 31, 2026 |
NCT06429800 | Not yet recruiting | Phase 1 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis | October 31, 2024 | April 2029 |
NCT05917288 | Not yet recruiting | Phase 1 | A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus | June 29, 2023 | January 4, 2025 |
NCT04749875 | Not yet recruiting | Study of Leukocyte Populations in Patients With Chronic Inflammatory | March 1, 2021 | March 1, 2026 | |
NCT06360068 | Not yet recruiting | Phase 2 | A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus | May 6, 2024 | May 1, 2025 |
NCT05791799 | Not yet recruiting | Phase 2/Phase 3 | Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus | April 1, 2023 | October 31, 2025 |
NCT06297408 | Not yet recruiting | Phase 1 | Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus | March 2024 | May 2026 |
NCT06400537 | Not yet recruiting | Phase 1 | Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus | May 2024 | May 2026 |
NCT05620407 | Recruiting | Phase 3 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | January 12, 2023 | December 17, 2027 |
NCT05631717 | Recruiting | Phase 3 | The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN | October 1, 2022 | December 31, 2025 |
NCT05632029 | Recruiting | N/A | Laser Acupuncture in Egyptian Systemic Lupus Females With Insulin Resistance | October 20, 2022 | March 30, 2023 |
NCT05637112 | Recruiting | A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice | February 27, 2023 | March 15, 2029 | |
NCT05638802 | Recruiting | Phase 1/Phase 2 | A Study of DS-7011a in Patients With Systemic Lupus Erythematosus | June 7, 2023 | March 15, 2025 |
NCT05639114 | Recruiting | Phase 3 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | March 2, 2023 | January 16, 2029 |
NCT05659407 | Recruiting | BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis | July 24, 2020 | January 31, 2023 | |
NCT05666336 | Recruiting | Phase 4 | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients | December 31, 2022 | June 30, 2024 |
NCT05687526 | Recruiting | Phase 1 | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus | May 25, 2023 | December 2024 |
NCT05689580 | Recruiting | N/A | The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity | September 1, 2022 | September 2024 |
NCT05698173 | Recruiting | N/A | Systemic Lupus Erythematosus and Accelerated Aging | September 8, 2023 | September 2025 |
NCT05704153 | Recruiting | N/A | Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) | September 30, 2022 | October 2024 |
NCT05714930 | Recruiting | N/A | LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus | December 12, 2023 | September 30, 2026 |
NCT05748899 | Recruiting | N/A | Effect of Applying Ujjayi Pranayama on Cortisol in Lupus Patients | December 15, 2022 | March 15, 2023 |
NCT05765006 | Recruiting | Phase 1 | CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus | February 24, 2023 | December 30, 2025 |
NCT05796206 | Recruiting | Phase 2/Phase 3 | A Clinical Study of MIL62 in Systemic Lupus Erythematosus | May 26, 2023 | July 2026 |
NCT05798117 | Recruiting | Phase 1/Phase 2 | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | February 28, 2023 | October 9, 2026 |
NCT05828147 | Recruiting | Phase 4 | Anti-CD20 Antibodies for Treatment of SLE-PAH | May 25, 2023 | March 2026 |
NCT05835310 | Recruiting | Phase 3 | An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | March 14, 2024 | January 15, 2030 |
NCT05835986 | Recruiting | Phase 1 | A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus | December 18, 2023 | November 30, 2027 |
NCT05843643 | Recruiting | Phase 3 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | July 19, 2023 | October 31, 2027 |
NCT05856448 | Recruiting | Phase 2 | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus | June 28, 2023 | April 2026 |
NCT05859191 | Recruiting | Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus | July 21, 2023 | July 2029 | |
NCT05866861 | Recruiting | Phase 1 | A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus | April 24, 2023 | July 2024 |
NCT05869955 | Recruiting | Phase 1 | A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases | September 13, 2023 | November 15, 2027 |
NCT05879419 | Recruiting | Phase 4 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | May 23, 2023 | May 22, 2027 |
NCT05880121 | Recruiting | Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus | April 30, 2023 | April 29, 2026 | |
NCT05900232 | Recruiting | N/A | Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus | May 15, 2023 | November 1, 2023 |
NCT05916781 | Recruiting | Phase 4 | Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus | July 1, 2023 | July 31, 2026 |
NCT05927688 | Recruiting | Assessment of Physician Consideration of ePRO's, From Patients With Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments | July 18, 2023 | July 2027 | |
NCT05971498 | Recruiting | Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients | August 14, 2023 | March 1, 2024 | |
NCT06001606 | Recruiting | Phase 3 | Immunogenicity, Reactogenicity of Shingrix in SLE | May 8, 2023 | April 24, 2025 |
NCT06041568 | Recruiting | Phase 1 | A Study of Imvotamab in Severe Systemic Lupus Erythematosus | August 15, 2023 | May 2026 |
NCT06056778 | Recruiting | The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA) | September 28, 2023 | June 30, 2024 | |
NCT06106893 | Recruiting | Phase 1/Phase 2 | A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus | January 12, 2024 | December 2026 |
NCT06119763 | Recruiting | AntiDFS70 Lupus Nephritis | October 15, 2023 | October 25, 2024 | |
NCT06121297 | Recruiting | Phase 1/Phase 2 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | February 16, 2024 | December 2027 |
NCT06133972 | Recruiting | Phase 3 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | May 21, 2024 | December 23, 2031 |
NCT06137053 | Recruiting | Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus | November 1, 2022 | December 31, 2025 | |
NCT06151990 | Recruiting | Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus | December 2023 | October 2025 | |
NCT06153095 | Recruiting | Phase 1/Phase 2 | A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) | February 15, 2024 | February 2027 |
NCT06161116 | Recruiting | Phase 2 | Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) | December 27, 2023 | July 9, 2027 |
NCT06222853 | Recruiting | Phase 1 | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus | January 4, 2024 | December 30, 2026 |
NCT06226324 | Recruiting | fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus | January 1, 2023 | December 2024 | |
NCT06255743 | Recruiting | N/A | (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE | February 14, 2024 | February 14, 2025 |
NCT06294236 | Recruiting | Phase 1 | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) | April 29, 2024 | March 2028 |
NCT06308770 | Recruiting | N/A | Fatigue in Lupus Intervention Programmes (FLIP) | April 8, 2024 | April 2027 |
NCT06308978 | Recruiting | Phase 1 | FT819 in Moderate to Severe Active Systemic Lupus Erythematosus | February 24, 2024 | September 30, 2042 |
NCT06316076 | Recruiting | Phase 1 | Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases | October 30, 2023 | June 2026 |
NCT06327724 | Recruiting | Belimumab in SLE Synovial Inflammation and Lymph Nodes | September 1, 2023 | March 1, 2025 | |
NCT06333483 | Recruiting | Phase 1 | A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) | February 2, 2024 | October 2025 |
NCT06347718 | Recruiting | Phase 1/Phase 2 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | July 17, 2023 | May 31, 2026 |
NCT06361745 | Recruiting | N/A | Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | April 2, 2024 | March 1, 2025 |
NCT06378736 | Recruiting | Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus | January 22, 2024 | March 23, 2026 | |
NCT06449794 | Recruiting | Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital | June 1, 2024 | June 1, 2025 | |
NCT00756769 | Recruiting | Systemic Lupus Erythematosus in Gullah Health | April 2003 | June 2027 | |
NCT00775476 | Recruiting | Phase 2 | Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine | March 31, 2022 | December 2027 |
NCT06428188 | Recruiting | Phase 1/Phase 2 | Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases | May 29, 2024 | December 28, 2026 |
NCT06411249 | Recruiting | Phase 4 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | June 4, 2024 | May 29, 2029 |
NCT02450396 | Recruiting | Pregnancy and Medically Assisted Conception in Rare Diseases | June 2014 | December 2025 | |
NCT02633163 | Recruiting | Phase 2 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | October 26, 2018 | June 2025 |
NCT03138941 | Recruiting | Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region | September 1, 2013 | December 31, 2032 | |
NCT03276923 | Recruiting | Maternal Autoimmune Disease Research Alliance (MADRA) Registry | January 1, 2018 | January 1, 2027 | |
NCT00001372 | Recruiting | Study of Systemic Lupus Erythematosus | February 10, 1994 | ||
NCT03370263 | Recruiting | BENLYSTA® Special Drug Use Investigation | January 15, 2018 | June 26, 2025 | |
NCT00198068 | Recruiting | Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) | September 2003 | March 2025 | |
NCT03802188 | Recruiting | Hydroxychloroquine in Systemic Lupus Erythematosus | May 9, 2018 | March 31, 2025 | |
NCT03816345 | Recruiting | Phase 1 | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | July 16, 2019 | August 31, 2024 |
NCT06462768 | Recruiting | Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis | November 27, 2023 | April 27, 2029 | |
NCT04077684 | Recruiting | Phase 2 | Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial | September 10, 2019 | December 31, 2024 |
NCT04276701 | Recruiting | N/A | Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases | March 10, 2021 | March 2026 |
NCT04320680 | Recruiting | N/A | Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation | October 13, 2020 | May 13, 2025 |
NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
NCT06458972 | Recruiting | Safety, Efficacy, and Compliance of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) | January 1, 2024 | August 31, 2024 | |
NCT04447053 | Recruiting | Phase 4 | Sequential Belimumab and T-cell Based Therapy in SLE | November 8, 2021 | May 20, 2025 |
NCT04486118 | Recruiting | Phase 2 | Centrally Acting ACE Inhibition in SLE | October 1, 2021 | November 1, 2025 |
NCT04516408 | Recruiting | N/A | Recombinant Zoster Vaccine in Stable SLE Patients | April 20, 2021 | September 30, 2023 |
NCT04532541 | Recruiting | Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus | November 25, 2020 | September 30, 2025 | |
NCT04582136 | Recruiting | Phase 2 | Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus | March 4, 2021 | May 1, 2025 |
NCT04747288 | Recruiting | Objective Measurement With TCM Pattern for AIDDES | February 1, 2021 | December 31, 2024 | |
NCT04751396 | Recruiting | Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | April 20, 2022 | April 15, 2025 | |
NCT04833465 | Recruiting | Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions | July 16, 2021 | December 1, 2023 | |
NCT04835883 | Recruiting | Phase 2 | Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients | September 26, 2019 | January 20, 2026 |
NCT04877691 | Recruiting | Phase 3 | Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | June 8, 2021 | November 16, 2026 |
NCT04895696 | Recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | October 11, 2021 | April 22, 2029 |
NCT04908865 | Recruiting | Phase 4 | Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) | October 21, 2021 | September 4, 2024 |
NCT04951427 | Recruiting | PRediction Of Flares In Lupus With autoantibodiEs and Chemokines | September 15, 2021 | August 1, 2024 | |
NCT04963296 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | October 26, 2021 | November 30, 2027 |
NCT04976465 | Recruiting | Phase 1 | Treatment and Clinical Outcomes Among SLE Patients in Pregnancy | January 1, 2018 | December 31, 2026 |
NCT05001737 | Recruiting | Phase 3 | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | December 15, 2021 | September 2025 |
NCT05007340 | Recruiting | ILD-SARDs Registry and Biorepository | August 24, 2021 | August 2026 | |
NCT05029336 | Recruiting | Phase 2 | Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | December 2024 | May 2031 |
NCT05039840 | Recruiting | Phase 2 | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus | November 10, 2021 | November 30, 2026 |
NCT05236491 | Recruiting | Phase 2/Phase 3 | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases | March 9, 2022 | December 2023 |
NCT05243875 | Recruiting | N/A | Lupus Education Alliance Program | November 1, 2023 | August 31, 2024 |
NCT05292456 | Recruiting | Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc | February 1, 2021 | December 2022 | |
NCT05306574 | Recruiting | Phase 3 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) | June 20, 2022 | September 21, 2025 |
NCT05306873 | Recruiting | Phase 2 | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus | October 28, 2022 | June 20, 2026 |
NCT00512694 | Recruiting | Duke Lupus Registry | July 2007 | June 2027 | |
NCT05339217 | Recruiting | Phase 3 | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus | February 7, 2023 | July 1, 2025 |
NCT05392790 | Recruiting | N/A | Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus | May 23, 2022 | December 30, 2023 |
NCT05433857 | Recruiting | Phase 2 | Probiotics in Systemic Lupus Erythematosus | June 10, 2022 | December 30, 2023 |
NCT05440422 | Recruiting | Phase 2 | The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | December 7, 2023 | August 1, 2024 |
NCT05451277 | Recruiting | At the Heart of the Matter - Speckle Tracking Echocardiography in Lupus Mothers and Their Offspring | April 1, 2021 | September 30, 2023 | |
NCT05539001 | Recruiting | Screening Biomarkers for Severe Lupus Based on Multi-omics Studies | February 1, 2023 | June 30, 2025 | |
NCT05540327 | Recruiting | Phase 2 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | September 16, 2022 | April 15, 2025 |
NCT05559671 | Recruiting | Phase 4 | Safety of the Herpes Zoster Subunit Vaccine in Lupus | December 21, 2023 | January 2027 |
NCT05617677 | Recruiting | Phase 3 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | January 12, 2023 | December 17, 2027 |
NCT05624749 | Recruiting | Phase 3 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | April 21, 2023 | January 23, 2029 |
NCT00479622 | Terminated | Phase 1 | Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus | August 2007 | May 2008 |
NCT02917265 | Terminated | Phase 2 | Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus | November 2015 | November 2018 |
NCT00111306 | Terminated | Phase 3 | Study of Epratuzumab in Systemic Lupus Erythematosus | June 2005 | March 2007 |
NCT02741362 | Terminated | Phase 1 | Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome | December 2015 | December 31, 2016 |
NCT02665364 | Terminated | Phase 2 | Phase IIb Study of IFN-K in Systemic Lupus Erythematosus | September 23, 2015 | February 4, 2020 |
NCT02533570 | Terminated | Phase 2 | Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus | July 2015 | June 5, 2017 |
NCT02514967 | Terminated | Phase 3 | CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis | June 2016 | February 28, 2017 |
NCT00849745 | Terminated | Phase 1 | Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases | January 2003 | July 2015 |
NCT05430854 | Terminated | Phase 2 | Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study | June 1, 2022 | October 31, 2023 |
NCT02408471 | Terminated | N/A | Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis | June 2002 | January 2015 |
NCT00504244 | Terminated | Phase 3 | Myfortic Versus Azathioprine in Systemic Lupus Erythematosus | July 2007 | August 2009 |
NCT02102594 | Terminated | Phase 2 | Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) | October 2014 | August 30, 2019 |
NCT02066311 | Terminated | Phase 2 | Nelfinavir in Systemic Lupus Erythematosus | September 2014 | June 2018 |
NCT00684255 | Terminated | Phase 1 | Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) | August 2007 | July 2008 |
NCT00626197 | Terminated | Phase 3 | A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) | February 15, 2008 | October 28, 2013 |
NCT00539838 | Terminated | Phase 3 | A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) | December 19, 2007 | July 12, 2011 |
NCT00000419 | Terminated | Phase 3 | Safety of Estrogens in Lupus: Hormone Replacement Therapy | April 1996 | August 2002 |
NCT01946880 | Terminated | Phase 2 | Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) | November 20, 2013 | July 3, 2019 |
NCT01781611 | Terminated | N/A | Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) | February 2013 | November 2017 |
NCT00739050 | Terminated | Phase 4 | Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) | September 19, 2007 | February 1, 2008 |
NCT04839315 | Terminated | Early Phase 1 | COVID-19 Vaccination in Rheumatic Disease Patients | February 15, 2021 | February 9, 2022 |
NCT01777256 | Terminated | Phase 2 | An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 | March 1, 2013 | March 31, 2014 |
NCT04700267 | Terminated | Phase 1 | A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus | December 28, 2020 | October 6, 2021 |
NCT01709474 | Terminated | Phase 2 | Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus | June 2013 | July 2014 |
NCT01689025 | Terminated | Phase 1 | An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) | September 2012 | February 2014 |
NCT00383214 | Terminated | Phase 3 | Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) | May 2005 | March 2007 |
NCT04335747 | Terminated | COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases | April 23, 2020 | July 1, 2021 | |
NCT01541670 | Terminated | Phase 1 | Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis | November 28, 2011 | December 31, 2012 |
NCT00297284 | Terminated | N/A | Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil | February 2006 | February 2007 |
NCT04141046 | Terminated | N/A | LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE | January 1, 2019 | March 8, 2024 |
NCT00732940 | Terminated | Phase 2 | Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) | October 2008 | March 2012 |
NCT01488708 | Terminated | Phase 3 | On Open-Label Study in Participants With Systemic Lupus Erythematosus | January 2012 | October 2015 |
NCT01240694 | Terminated | Phase 3 | A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus | December 9, 2010 | June 14, 2012 |
NCT03953261 | Terminated | Phase 2 | Effect of Curcumin on Systemic Lupus Erythematosus | September 1, 2019 | April 13, 2022 |
NCT01164917 | Terminated | Phase 1 | Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus | August 2010 | March 2013 |
NCT00430677 | Terminated | Phase 2/Phase 3 | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis | June 2007 | August 2011 |
NCT03937856 | Terminated | N/A | Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases | May 7, 2019 | April 22, 2021 |
NCT03843125 | Terminated | Phase 3 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | September 9, 2019 | April 1, 2022 |
NCT03656627 | Terminated | Phase 1 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | June 27, 2019 | March 18, 2021 |
NCT03616912 | Terminated | Phase 3 | A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus | August 2, 2018 | March 9, 2022 |
NCT00203151 | Terminated | Phase 2 | A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus | July 2005 | February 2007 |
NCT03186794 | Terminated | N/A | Aerobic Exercise in Women With Systemic Lupus Erythematosus | February 22, 2018 | February 25, 2021 |
NCT03159936 | Terminated | Early Phase 1 | Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) | April 3, 2017 | June 10, 2020 |
NCT02975336 | Terminated | Phase 2 | A Phase II Study of M2951 in SLE | January 4, 2017 | March 23, 2020 |
NCT04275193 | Unknown status | Phase 2/Phase 3 | The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus | October 22, 2019 | September 1, 2022 |
NCT00004375 | Unknown status | Phase 2 | Ultraviolet Light Therapy for Systemic Lupus Erythematosus | September 1991 | |
NCT00006055 | Unknown status | N/A | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | March 2000 | |
NCT00017641 | Unknown status | Phase 1 | Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus | April 2001 | |
NCT00037128 | Unknown status | Phase 3 | Study of GL701 in Men With Systemic Lupus Erythematosus | March 1998 | |
NCT00172666 | Unknown status | Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) | August 2005 | July 2006 | |
NCT00188188 | Unknown status | Phase 4 | Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease | March 2002 | |
NCT00188357 | Unknown status | N/A | HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus | August 2003 | |
NCT00432354 | Unknown status | Phase 2/Phase 3 | An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus | March 2007 | March 2009 |
NCT00441220 | Unknown status | Cyclophosphamide in Lupus Nephritis | October 2006 | October 2010 | |
NCT00519454 | Unknown status | Estrogen and Gender Biased Autoimmunity | April 2005 | December 2013 | |
NCT00527176 | Unknown status | Pulse Corticosteroid Therapy and Effect on Brain Water Diffusivity | September 2007 | September 2007 | |
NCT00671047 | Unknown status | The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study | December 2007 | June 2010 | |
NCT00747578 | Unknown status | Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan | September 2008 | ||
NCT00750971 | Unknown status | Phase 2 | Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST) | August 2008 | August 2020 |
NCT00866229 | Unknown status | Phase 4 | Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level | April 2008 | June 2010 |
NCT00985803 | Unknown status | Phase 1 | Physical Activity in Patients With Systemic Lupus Erythematosus | November 2009 | March 2010 |
NCT01460680 | Unknown status | Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE) | November 2011 | June 2013 | |
NCT01515163 | Unknown status | N/A | Exercise and Systemic Lupus Erythematosus | May 2010 | July 2016 |
NCT01642706 | Unknown status | Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments | July 2, 2012 | December 2020 | |
NCT01687192 | Unknown status | Phase 2 | Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. | October 2012 | November 2016 |
NCT01712529 | Unknown status | N/A | Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients | September 2010 | November 2012 |
NCT01741857 | Unknown status | Phase 1/Phase 2 | Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus | January 2012 | December 2013 |
NCT01840709 | Unknown status | N/A | Effectiveness Study of Psychotherapy in Systemic Lupus Erythematosus | August 2010 | February 2014 |
NCT01863641 | Unknown status | Phase 2 | The Effect of Calcitriol on Progress and Activity of Lupus Nephritis | April 2013 | April 2014 |
NCT01956188 | Unknown status | N/A | Omega 3 in LES and APS | May 2014 | December 2017 |
NCT02037971 | Unknown status | N/A | Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus. | February 2013 | March 2015 |
NCT02270970 | Unknown status | Phase 4 | Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy | October 2014 | December 2019 |
NCT02403115 | Unknown status | Prediction of Outcome of Lupus Nephritis | October 2014 | November 2022 | |
NCT02465580 | Unknown status | Phase 2 | A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus | June 2015 | December 2017 |
NCT02558517 | Unknown status | Phase 3 | Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus | January 2014 | January 2018 |
NCT02801812 | Unknown status | Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus | January 2016 | June 2018 | |
NCT03142412 | Unknown status | Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization | April 17, 2017 | October 17, 2021 | |
NCT03165682 | Unknown status | Fatigue, Depression, and Cortical Excitability in Systemic Lupus | December 1, 2018 | December 30, 2019 | |
NCT03171103 | Unknown status | Systemic Lupus and Adverse Pregnancy Outcome | May 1, 2017 | May 1, 2020 | |
NCT03178721 | Unknown status | Regulatory BCells in Systemic Lupus Erythematosus | June 25, 2017 | July 25, 2018 | |
NCT03219801 | Unknown status | Early Phase 1 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus | August 1, 2017 | December 30, 2019 |
NCT03296995 | Unknown status | N/A | Accuracy, Feasibility and Acceptance of CGM Lupus | July 1, 2017 | October 1, 2019 |
NCT03348774 | Unknown status | Scrutinizing the Heterogeneity of SLE: Defining Phenotypes | February 9, 2017 | July 30, 2018 | |
NCT03396393 | Unknown status | Phase 2 | Exploratory Study of DHA in Systemic Lupus Erythematosus Patients | March 2018 | December 2022 |
NCT03446339 | Unknown status | Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE) | August 3, 2017 | December 2023 | |
NCT03459274 | Unknown status | Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology | March 16, 2018 | June 2018 | |
NCT03583853 | Unknown status | Autophagy in Systemic Lupus Erythematosus | July 1, 2019 | December 1, 2020 | |
NCT03746028 | Unknown status | The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies | June 6, 2018 | January 30, 2024 | |
NCT03804723 | Unknown status | N/A | Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus | June 2019 | September 2023 |
NCT03878303 | Unknown status | Phase 1 | Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE) | November 28, 2018 | December 2021 |
NCT03919643 | Unknown status | BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE | May 1, 2019 | July 1, 2020 | |
NCT04022655 | Unknown status | Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit | July 22, 2019 | October 2019 | |
NCT04046172 | Unknown status | N/A | Treatment of Periodontal Disease in Systemic Lupus Erythematosus | November 1, 2021 | June 1, 2023 |
NCT04110184 | Unknown status | Haematological Indices in Systemic Lupus Erythematosus | December 1, 2019 | February 1, 2023 | |
NCT04293510 | Unknown status | Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus | July 15, 2020 | July 15, 2022 | |
NCT04356014 | Unknown status | Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus | April 1, 2020 | December 30, 2020 | |
NCT04397237 | Unknown status | Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe | June 10, 2020 | January 2021 | |
NCT04431167 | Unknown status | N/A | Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus: The Living Well With Lupus Study | September 1, 2020 | December 1, 2022 |
NCT04515719 | Unknown status | Phase 4 | Efficacy and Safety of Belimumab in SLE Patients | March 19, 2021 | June 1, 2023 |
NCT04530461 | Unknown status | Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases | June 1, 2020 | January 31, 2021 | |
NCT04558814 | Unknown status | N/A | Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage | January 2021 | December 2022 |
NCT04648059 | Unknown status | Epigenetics in Lupus Nephritis | December 1, 2020 | June 30, 2023 | |
NCT04799730 | Unknown status | Expression of CXCR4 in Patients With Systemic Lupus Erythematosus | May 2021 | May 2022 | |
NCT04810754 | Unknown status | Phase 2 | An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus | June 30, 2021 | December 31, 2023 |
NCT04942314 | Unknown status | Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study | July 1, 2021 | June 1, 2023 | |
NCT04971590 | Unknown status | Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis | September 14, 2021 | January 30, 2023 | |
NCT04983784 | Unknown status | N/A | The Effectiveness of Walking in Patients With Systemic Lupus Erythematosus | November 1, 2020 | July 30, 2021 |
NCT05030779 | Unknown status | Early Phase 1 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus | September 10, 2021 | September 10, 2022 |
NCT05045417 | Unknown status | IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage | October 1, 2021 | April 30, 2022 | |
NCT05057481 | Unknown status | Phase 3 | Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus | September 15, 2021 | January 15, 2023 |
NCT05090189 | Unknown status | N/A | Exercise and Nutrition Recommendations for Patients Using Glucocorticoids (ENRG) | August 27, 2021 | November 2023 |
NCT05105217 | Unknown status | Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients | December 1, 2021 | February 1, 2023 | |
NCT05132621 | Unknown status | The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy. | November 2021 | December 2023 | |
NCT05157334 | Unknown status | N/A | The Effect of Deep Breathing and Transcutaneus Electrical Nerve Stimulation on Heart Rate Variability | September 1, 2021 | September 2022 |
NCT05179018 | Unknown status | Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus | March 1, 2022 | August 1, 2023 | |
NCT05253638 | Unknown status | N/A | Evaluation Of Serum MIF Level in SLE Patients | February 22, 2022 | December 28, 2022 |
NCT05262686 | Unknown status | Phase 3 | Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus | April 1, 2022 | June 1, 2023 |
NCT05315739 | Unknown status | N/A | Vagus Nerve Stimulation for Systemic Lupus Erythematous | May 2022 | September 2023 |
NCT05358652 | Unknown status | Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy | October 15, 2021 | January 15, 2023 | |
NCT05362812 | Unknown status | Prediction of Lupus Renal Flares Study | February 28, 2022 | April 1, 2023 | |
NCT05381545 | Unknown status | N/A | Laser Puncture and Program of Lifestyle Modification in Lupus Females | February 28, 2022 | July 1, 2022 |
NCT05418855 | Unknown status | Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit | July 1, 2022 | February 1, 2023 | |
NCT03937271 | Withdrawn | Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome | April 1, 2019 | December 31, 2020 | |
NCT03204448 | Withdrawn | Clinical Performance of BioCLIA Ro60 | May 8, 2017 | April 16, 2020 | |
NCT02525835 | Withdrawn | N/A | Tissue Sodium in Autoimmune Disease | December 1, 2018 | August 2020 |
NCT02331810 | Withdrawn | Phase 1 | Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients | April 2016 | May 2017 |
NCT02270710 | Withdrawn | Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease | April 2013 | October 2016 | |
NCT02074020 | Withdrawn | Phase 3 | CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis | December 2015 | |
NCT01440231 | Withdrawn | Phase 2 | Atacicept Demonstrating Dose RESponSe | February 2012 | February 2014 |
NCT01359826 | Withdrawn | Phase 4 | The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients | October 2011 | November 2013 |
NCT01276782 | Withdrawn | Phase 4 | Levothyroxine in Pregnant SLE Patients | January 2011 | June 2011 |
NCT01018238 | Withdrawn | Phase 1 | An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE) | November 2009 | November 2009 |
NCT00858884 | Withdrawn | N/A | Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus | August 2006 | August 2006 |
NCT00752999 | Withdrawn | Phase 2 | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | November 2008 | March 2010 |
NCT00610805 | Withdrawn | N/A | Cardiology Prevention in Systemic Lupus Erythematosus (SLE) | November 2009 | November 2009 |
NCT00508898 | Withdrawn | Phase 4 | The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria | May 2008 | September 2009 |
NCT00390091 | Withdrawn | Phase 2 | Study of LJP 394 (Abetimus Sodium) in Lupus Patients | September 2006 | |
NCT00382837 | Withdrawn | Phase 3 | Study of Epratuzumab in Systemic Lupus Erythematosus | January 2007 | |
NCT00278590 | Withdrawn | Phase 1 | Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus | July 2004 | July 2015 |
NCT00230035 | Withdrawn | Phase 2 | Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) | September 2005 |
- Disase is a (Disease Ontology)
- DOID:8857
- Cross Reference ID (Disease Ontology)
- GARD:10253
- Cross Reference ID (Disease Ontology)
- ICD10CM:M32.9
- Cross Reference ID (Disease Ontology)
- ICD9CM:710.0
- Cross Reference ID (Disease Ontology)
- KEGG:05322
- Cross Reference ID (Disease Ontology)
- MESH:D008180
- Cross Reference ID (Disease Ontology)
- MIM:152700
- Cross Reference ID (Disease Ontology)
- MIM:300809
- Cross Reference ID (Disease Ontology)
- MIM:605480
- Cross Reference ID (Disease Ontology)
- MIM:608437
- Cross Reference ID (Disease Ontology)
- MIM:609903
- Cross Reference ID (Disease Ontology)
- MIM:609939
- Cross Reference ID (Disease Ontology)
- MIM:610065
- Cross Reference ID (Disease Ontology)
- MIM:610066
- Cross Reference ID (Disease Ontology)
- MIM:612254
- Cross Reference ID (Disease Ontology)
- MIM:612378
- Cross Reference ID (Disease Ontology)
- MIM:613145
- Cross Reference ID (Disease Ontology)
- MIM:614420
- Cross Reference ID (Disease Ontology)
- NCI:C3201
- Cross Reference ID (Disease Ontology)
- ORDO:536
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:156450004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0024141
- Exact Synonym (Disease Ontology)
- disseminated lupus erythematosus
- Exact Synonym (Disease Ontology)
- Lupus Erythematosus, systemic
- Exact Synonym (Disease Ontology)
- SLE - Lupus Erythematosus, systemic
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002725
- ICD10 preferred id (Insert disease from ICD10)
- D0010455
- ICD10 class code (Insert disease from ICD10)
- M32